BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Darunavir/Cobicistat/Emtricitabine/Tenofovir

Post Treatment Acture Exacerbation of Hepatitis B

  • Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of SYMTUZA. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue SYMTUZA. If appropriate, anti-hepatitis B therapy may be warranted

Patient Counseling Information

Package Inserts

Darunavir/Cobicistat/Emtricibine/Tenofovir

Additional Information

Updated August 2018